Edoardo Mannucci, Besmir Nreu, Chiara Montereggi, Benedetta Ragghianti, Marco Gallo, Andrea Giaccari, Matteo Monami
AIMS: Meta-analyses of randomized trials on Dipeptidyl Peptidase-4 inhibitors (DPP4i) reported discordant results on major cardiovascular events (MACE), mortality, and heart failure. Aim of this meta-analysis of randomized trials is the assessment of the cardiovascular safety of DPP4i. DATA SYNTHESIS: A Medline, Embase, Cochrane database search for sitagliptin, vildagliptin, omarigliptin, saxagliptin, alogliptin, trelagliptin, anagliptin, linagliptin, gemigliptin, evogliptin, and teneligliptin was performed up to up January 1st, 2020...
September 22, 2021: Nutrition, Metabolism, and Cardiovascular Diseases: NMCD